Data justify further research on potential of psychedelics in treating psychiatric disorders

A literature review concludes that current research does not yet support using psychedelic compounds to treat psychiatric disorders, but the existing evidence justifies further investigation. The strongest evidence points to psilocybin and MDMA, both of which have received FDA breakthrough therapy designation to speed up evaluation and development as potential treatments for serious illnesses.

Study at a glance

Abstract

Although research findings to date do not support the use of psychedelic compounds in the treatment of psychiatric disorders, the existing body of research justifies continued investigation, a literature review concludes. The review found the most significant evidence supporting use of psilocybin and 3,4‐methylenedioxymethamphetamine (MDMA). Both of these drugs have been given “breakthrough therapy” designation by the Food and Drug Administration (FDA), which is intended to expedite the evaluation and development of drug candidates that might offer significant advantages over existing treatments for serious illnesses.